Marit Sjo Lorentzen

Patrimonio netto: 49 562 $ in data 31/05/2024

56 anni

Health Technology

Consumer Services

Posizioni attive di Marit Sjo Lorentzen

Società	Posizione	Inizio	Fine
ARCTICZYMES TECHNOLOGIES ASA	Direttore operativo	-	-
ARCTICZYMES TECHNOLOGIES ASA	Direttore/Membro del Consiglio	-	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Direttore/Membro del Consiglio	-	-

University of Tromso

Undergraduate Degree

Distribuzione geografica

Norvegia

Posizioni

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Aziende private	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Aziende private

Health Technology